Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

From a Western clinical viewpoint, PSC and IBD are interwoven conditions connected by the gut–liver axis. Epidemiologic data show that most people with PSC have IBD—typically ulcerative colitis with extensive, sometimes subtly symptomatic colitis—while a smaller fraction of those with IBD develop PSC. The coexistence of PSC reshapes risk: colorectal cancer risk is markedly higher in PSC‑IBD than in IBD alone, and hepatobiliary cancers (cholangiocarcinoma, gallbladder cancer) become key concerns. Accordingly, guidelines recommend colonoscopy at the time of PSC diagnosis and at close intervals thereafter, using high‑definition imaging and often dye‑spray chromoendoscopy, alongside gallbladder surveillance and vigilance for dominant bile‑duct strictures. Mechanistically, translational studies highlight immune cell trafficking between gut and liver. Gut‑primed lymphocytes can home to the biliary tree via hepatic expression of mucosal addressins (MAdCAM‑1) and enzymes (VAP‑1), while microbial dysbiosis and barrier dysfunction expose the liver to bacterial products via the portal circulation. Genetics—especially HLA variants—further predispose to this coupled inflammatory state. Management is dual‑track. For PSC, ursodeoxycholic acid may improve cholestatic enzymes but has not improved transplant‑free survival, and high doses are discouraged. Endoscopic therapy addresses dominant strictures and cholangitis risk. Liver transplantation remains definitive for advanced disease, with recognition that IBD activity may change post‑transplant. For IBD, standard therapies (5‑ASA, corticosteroids for flares, biologics such as anti‑TNF, vedolizumab, or ustekinumab) are used, though none convincingly alters PSC progression. Emerging approaches—oral vancomycin, microbiome‑directed therapies, nor‑UDCA—are under study but not yet established for long‑term outcomes. Across this landscape, coordinated hepatology–gastroenterology care and proactive cancer surveillance are central to improving quality of life and long‑term prognosis.

Traditional and integrative frameworks interpret PSC‑IBD through a holistic lens in which digestive fire, detoxification, and bile flow are intimately connected with systemic inflammation. In TCM, many patients fit patterns of Damp‑Heat in the Liver–Gallbladder network combined with Spleen Qi deficiency: stagnation and heat manifest as cholestasis, pruritus, and right‑sided discomfort, while Spleen deficiency contributes to loose stools, fatigue, and food sensitivity. Treatment principles include clearing Damp‑Heat (e.g., Yin Chen Hao–based formulas), harmonizing the middle burner to soothe colitis, and moving Blood to address fibrosis and pain—always individualized and supervised by trained practitioners. Ayurveda frames similar dynamics as aggravated Pitta (heat/inflammation) with impaired Agni and accumulation of Ama, guiding cooling, easily digested diets, gentle bitters, and anti‑inflammatory botanicals such as Guduchi and turmeric (Haridra). Integrative care emphasizes foundations: nourishment tailored to tolerance (e.g., Mediterranean‑style patterns during remission; simplified, low‑irritant meals during flares), restoration of microbial balance (select probiotics and, investigationally, FMT), and stress modulation through meditation, breathwork, and restorative movement. Evidence for curcumin as an adjunct in mild‑to‑moderate ulcerative colitis is relatively robust, while bile‑duct outcomes remain untested. Acupuncture may help pain, motility, and stress reactivity, though data specific to PSC are lacking. Safety is paramount: some botanicals (e.g., indigo naturalis) have documented hepatobiliary adverse effects despite UC efficacy, and herb–drug interactions are possible. Within a collaborative model, these approaches can complement guideline‑directed hepatology and gastroenterology care, aiming to reduce symptom burden, support liver and gut resilience, and enhance overall well‑being.